Cleveland Clinic is a founding scientific partner in MQ Foundation's flagship research initiative, a five-year study led by Dr. Tatiana Falcone examining suicide risk in youth ages 15–24. Using MEG neuroimaging alongside the CAMS clinical intervention, the study is working to identify measurable neural signatures tied to hopelessness, risk, and treatment response — the foundation for a future predictive model that could help clinicians identify at-risk youth with far greater precision than is possible today. Cleveland Clinic's world-class clinical infrastructure and research expertise make this ambitious work possible, and its partnership reflects a shared commitment to turning fundamental questions about the brain into real progress for the young people who need it most.

As a mission-aligned mental health organization, the American Foundation for Suicide Prevention has been a valuable partner in MQF’s work to invest in mental health research across the United States. Since MQF’s founding, AFSP has partnered with the Foundation multiple times to fund the work of promising US-based MQ Fellows, including Dr. Marisa Marraccini. In 2022, AFSP’s Chief Medical Officer, Dr. Christine Yu Moutier, sat on the panel of experts convened by MQ to help evaluate and select Fellows for the Gone Too Soon program — MQ’s biggest investment in research to date.

MQ Foundation, in partnership with The Kennedy Forum, has launched a one-year fellowship in economics & mental health research to address a critical and underexamined dimension of the youth mental health crisis: its economic impact. The fellowship builds on research linking adolescent psychological distress to reduced employment, lower lifetime earnings, and increased public spending — translating these insights into a free, open-source policy tool that helps federal and state leaders weigh the return on investment of prevention and early intervention. The fellowship is embedded within The Kennedy Forum's broader work on youth mental health and system transformation, including its ambitious 90-90-90 goals: by 2033, 90% of youth will be screened for mental health challenges, 90% of those identified will receive evidence-based treatment, and 90% of those treated will experience improved outcomes. 

MQ Foundation has partnered with the EMDRIA Foundation to advance the science behind EMDR (Eye Movement Desensitization and Reprocessing) — a proven, phase-based therapy that helps people process and heal from trauma and distressing memories.

Together, we're funding research that brings much-needed rigor to a field where clinical use has outpaced research investment. Despite EMDR's widespread adoption in trauma care, high-quality research funding has lagged behind — and that gap is exactly what this partnership is designed to close. Our joint research call prioritizes studies that strengthen EMDR's evidence base and clinical utility across North America. This partnership builds on MQ Foundation's track record of designing and delivering high-impact research projects. The result: more researchers equipped to do rigorous work, and more people gaining access to trauma care that's backed by evidence.